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Abstract
Background: Kawasaki disease (KD) is an autoimmune disease preferentially attacking children younger than five
years worldwide. So far, the principal treatment to KD is the administration of Intravenous immunoglobulin (IVIG).
Although DNA methylation plays important regulation roles in diseases, few studies investigated the regulation
roles of DNA methylation in KD.
Methods: In this study, we focused not only on the DNA methylation alterations resulted from KD onset but also
on DNA methylation alterations resulted from IVIG administration. To do so, we investigated the effects of KD’s
onset and IVIG administration on CpG marker’s methylation alterations.
Results: We first found that DNA methylation alterations reflecting disease onset or IVIG administration are
contributed mainly by the CpG markers on autosomes. In addition, we also demonstrated that some CpG markers
carry methylation alteration among samples, forcing the expression abundance of the downstream genes to be
also altered and negatively correlated with methylation profile. Finally, compared with KD’s onset, IVIG
administration brings stronger impact on methylation alteration. And, such alterations were conducted mainly by
hyper-methylating CpG markers, forcing the corresponding genes to keep lower expression levels. Moreover, the
genes regulated by the altered CpG markers with IVIG administration are enriched in the pathways associated with
inflammatory immune response.
Conclusions: In summary, our result provides researchers with another way into the regulation mechanism
through which IVIG represses excessive inflammatory responses.
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Background
Kawasaki disease (KD), also called mucocutaneous
lymph node syndrome, is a childhood systemic vasculitis.
It was first described by Dr. Tomisaku Kawasaki in 1967
[1]. KD mainly affects small to mediums sized vessels,
with the development of coronary artery aneurysms
being the most severe complication of KD. If left un-
treated, coronary artery lesions may develop in up to
25 % of patients with KD, which increases the risk of
coronary artery aneurysm formation, coronary artery
thrombosis, myocardial infarction or even sudden death
[2, 3]. Current treatment guidelines for KD include
intravenous immunoglobulin (IVIG) therapy during the
acute phase. IVIG is given within the first ten days of
fever and it may reduce the risk of coronary artery for-
mation to 2–4 % [4]. In addition to treating KD, IVIG is
also applied in treating patients with primary immune
deficiency or acute infection by maintaining adequate
level of IgG in circulation system and enhancing im-
mune ability. However, in KD patients, IVIG represses
excessive inflammation rather than enhances immune
ability. Actually, there is still a debate on the precise
mechanism by which IVIG represses immune response
and that’s why we are curious about the methylation al-
teration after IVIG administration.
The exact pathogenesis of KD is still a matter of de-
bate, although existing research points to both environ-
mental and genetic factors. KD appears to be associated
with ethnicity, and is more prevalent in Asian children
[5]. Retrospective studies have also found that children
whose parents or siblings were attacked by KD are at a
higher risk of developing the disease [6, 7]. Genetic poly-
morphisms have also been identified in patients with
KD, most of which have been associated with B cell and
T cell immunity [8–10]. Apart from genetic factors, KD
tends to occur in seasonal clusters suggesting an infec-
tious or transmissible triggering agent [11].
DNA methylation plays an important role in regulation
of gene expression through establishing and maintaining
the DNA methylation status in gene promoters [12]. In
mammals, within promoter regions, when the methyl
group is chemically bounded to the cytosine of the CpG di-
nucleotide (also called CpG marker), the expression abun-
dance of the downstream gene is usually decreased. There-
fore, by hypo- or hyper-methylating the CpG markers at
the promoter regions, DNA methylation performs regula-
tion abilities in diseases, especially when the downstream
genes are functionally related to diseases [13–15].
In our previous study, we investigated the regulation
roles of DNA methylation in KD by comparing the CpG
markers’ methylation profiles between control and KD
patients [16, 17]. We concluded that the CpG markers
in FCGR2A promoter are hypo-methylated in KD pa-
tients, increasing the expression abundance of FCGR2A.
In this study, we focused not only on the DNA methyla-
tion alterations resulted from KD onset but also on
DNA methylation alterations resulted from IVIG admin-
istration. To do so, we collected DNA sample from con-
trol subjects, KD patients before IVIG treatment and KD
patients after IVIG treatment. By bisulfite conversion of
DNA samples and microarray detection of methylation
profile, we investigated the effects of KD’s onset and
IVIG administration on CpG marker’s methylation
alterations.
Methods
Collection of subjects and clinical DNA samples
In Kaohsiung Chang Gung memorial Hospital, Taiwan,
we enrolled 4 febrile control subjects (FC), 7 KD pa-
tients at acute phase (KD1) and 7 KD patients three
weeks after IVIG treatment (KD3). Here, FC denotes fe-
brile control, including the patients with fever but not
diagnosed as KD by a physician. We collected whole
blood samples from the subjects based on the IRB ap-
provals by the Chang Gung Memorial Hospital (No.101-
0680A3). Each KD3 subject was treated with IVIG (2
gm/kg) over a 12-hour period. Blood cells were collected
and subjected to DNA extraction followed by bisulfite
conversion of genomic DNA samples.
Profiling of CpG methylation
We used Illumina HumanMethylation27 BeadChip to
perform the genome-wide screening of DNA methyla-
tion patterns. HumanMethylation27 BeadChip was de-
signed to detect methylation patterns of 27,578 CpG
markers, spanning human genome. Detailed information
of HumanMethylation27 BeadChip is available via the fol-
lowing URL: http://support.illumina.com/array/array_kits/
infinium_humanmethylation27_beadchip_kit.html. For each
HumanMethylation27 BeadChip assay, 200 ng of bisulfite-
converted genomic DNA was applied according to the
manufacturer’s instructions. For each CpG markers,
HumanMethylation27 BeadChip designs two probes to
distinguish cytosine (originally methylated) from thymine
(originally un-methylated so that converted into uracil by
bisulfite treatment and converted into thymine by reverse
PCR reaction). By detecting the relative intensities of the
probes for cytosine and thymine, methylation percentages
(named β values) are determinable.
Results and discussion
Summary of significantly altered CpG markers on
chromosomes
In this study, we used Illumina HumanMethylation27
BeadChip to evaluate methylation patterns of CpG
markers in FC (febrile control), KD1 (KD patients at the
acute phase) and KD3 (KD patients three weeks after
IVIG treatment) samples, comprising three comparisons
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namely KD1 vs. FC, KD3 vs. FC and KD3 vs. KD1.
When the p < 0.05 criterion was set, we detected 3,249,
5,438 and 5,353 significantly altered CpG markers in
KD1 vs. FC, KD3 vs. FC and KD3 vs. KD1 comparisons,
respectively. For an overall understanding on the loca-
tions of significantly altered CpG markers on chromo-
somes, we investigated the distribution of significance
rate, defined as the ratio of the number of significantly
altered CpG markers to the one of all CpG markers on
each chromosome. Figure 1 shows that the significance
rate for KD1 vs FC comparison is evenly distributed on
most chromosomes. In the other two comparisons, sig-
nificance rate becomes significantly much higher and
more diverse than the one in KD1 vs FC comparison.
Figure 1 also demonstrates that fewer altered CpG
markers distribute on X and Y chromosomes, implying
that the DNA methylation alterations reflecting disease
onset or IVIG treatment are contributed mainly by auto-
somes. Since higher methylation leads to lower gene ex-
pression, disease onset or IVIG treatment have little
impact on the expressions of the genes sex chromo-
somes, especially on X chromosome.
Major alterations in DNA methylation patterns caused by
IVIG treatment
Next, we are interested in how significant the altered
CpG markers are. Therefore, we generated a Manhattan
plot for each comparison. As shown in Fig. 2, even with
more stringent criteria (less p value), consistently, fewer
CpG markers altered in the KD1 vs FC comparison than
the other two ones, which implies that IVIG treatment
causes major alterations in DNA methylation patterns.
In addition, the effect of IVIG administration on the
methylation alteration of CpG marker is much stronger
than disease itself, which is proved by Fig. 3. In Fig. 3,
the FC, KD1 and KD3 samples are exactly clustered
based on their sample characteristics. In terms of the
methylation patterns of CpG markers, FC and KD1 sam-
ples are pretty similar; while, KD3 samples carry much
higher divergence. Figure 3 also shows that most signifi-
cantly altered CpG markers are hypo-methylated in FC
and KD1 sample; while, most cases in KD3 sample are
hyper-methylated. Therefore, based on methylation
regulation theory, in FC and KD1 samples, most genes
regulated by the significantly altered CpG markers
should be activated; while, the ones in KD3 samples
should keep lower expression levels.
Results of pathway enrichment analysis on the CpG
marker related genes
IVIG is widely applied in autoimmune disease, including
KD, to repress harmful inflammation [18]. To understand
what genes are regulated by the significantly altered CpG
markers with IVIG administration, we derived the genes
nearby the markers followed by pathway enrichment ana-
lysis on the genes. From a list of input genes, pathway en-
richment analysis tries to identify the pathways significantly
enriched by the input genes based on a hypergeometric test.
And, pathway enrichment analysis provides more inform-
ative data, enabling the researchers consider the genes in a
functional unit rather the individual gene [19]. After path-
way enrichment analysis, a list of significant pathways were
generated from the input genes in both KD3 vs FC and
KD3 vs KD1 comparisons. We took the intersection of the
two lists, presenting the pathways in Table 1.
Table 1 demonstrates that the significant pathways shared
by the two comparisons are Hematopoietic cell lineage,
Cytokine-cytokine receptor interaction, Chemokine signal-
ing pathway and Jak-STAT signaling pathway. Through the
hematopoietic cell lineage pathway, hematopoietic stem cell
differentiates into different blood cells, including T cell, NK
cell, basophil, macrophage, B cell and so on, responding to
diverse stimulus or necessity [20]. Therefore, hematopoietic
cell lineage plays important roles in immune response.
Fig. 1 Distribution of significance rate along with chromosome. For each chromosome, we first tabulated the number of CpG markers on it.
Then, the significance rate was defined as the ratio of the number of significantly altered CpG markers to the number of all CpG markers on the
chromosome. The average significance rates for KD1 vs FC, KD3 vs FC and KD3 vs KD1 are 11.88, 19.30 and 19.13 %, respectively. In addition, the
standard deviations for them are in order 1.91, 3.76 and 3.19 %. Significance was determined with p < 0.05 from t-test
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Fig. 3 HeatMap of significantly altered CpG markers. By the union of three comparisons, including KD1 vs. FC, KD3 vs. FC and KD3 vs. KD1, there
are totally 9,234 significantly altered CpG markers. The heatmap shows that methylation alteration caused by IVIG treatment is much more
significant than the one caused by disease, which is consistent with the result in Fig. 2. Significance was determined with p < 0.05 from t-test
Fig. 2 Manhattan plot of significant CpG markers. a, b and c belong to KD1 vs. FC, KD3 vs. FC and KD3 vs. KD1 comparisons, respectively. The ‘P’ in X axis
denotes the p value of ANOVA analysis. Figure 2 shows that fewer CpG markers altered in KD1 vs. FC comparison than other two ones. The Manhattan
plots were generated with R package ‘qqman’
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Cytokine are soluble proteins, secreted by donor cells
responding to stimulus and transported by circulation sys-
tem to target cells. Through the cytokine-cytokine receptor
interaction pathway, cytokines bind to their receptors on
the target cell membrane [21]. Next, through the Jak-STAT
signaling pathway, the external signals initiated by cytokines
can be passed down into the target cells, triggering immune
activities and activating inflammation responses [22]. Simi-
lar to cytokine, chemokine also plays positive roles in up-
regulating inflammatory immune responses [23]. Therefore,
the pathways altered by IVIG administration are immune-
related. They play either up-stream or down-stream roles
in regulating inflammatory immune response.
Actually, there is still a debate on the precise mechanism
by which IVIG represses immune response, although sev-
eral possible mechanisms have been proposed [24–28]. Our
results of pathway enrichment analysis shows that IVIG ad-
ministration performs the ability of repressing harmful in-
flammation through hypo- or hyper-methylating the CpG
markers whose down-stream genes are involved inflamma-
tory immune response. Such result provides the researchers
with another way into the regulation mechanism through
which IVIG represses excessive inflammatory responses.
Although our result provides researchers with another way
into the regulation mechanism through which IVIG
represses excessive inflammatory responses, we can not ex-
clude the involvement of aspirin. Salicylic acid is the major
compound of aspirin and is usually administrated with
IVIG for alleviation of excessive inflammatory immune re-
sponse. Therefore, the effect of salicylic acid on methylation
alteration needs more attentions.
Methylation alteration between samples
Figure 3 also shows that a small fraction of CpG markers
are characterized with altered methylation patters be-
tween samples. Figure 4 illustrates 11 CpG markers that
are significantly altered (p < 0.05) and carry more than
10 % alteration in at least two of the three comparisons.
The first six CpG markers are hyper-methylated in KD1
samples when compared with FC samples where the
average methylation percentages are set to 100 %. So,
the onset of KD increases the methylation degree on these
markers. However, with the administration of IVIG, these
markers did not significantly recover from the hyper-
methylated status. Another kind of CpG markers with al-
tered methylation patters are the last 5 markers that are
hypo-methylated in KD1 samples when compared with
FC ones. So, the onset of KD decreases the methylation
degree on these markers. Moreover, with the administra-
tion of IVIG, two markers (cg06768707 and cg26465666)
Table 1 The results of pathway enrichment analysis. We did pathway enrichment analysis with Partek on the genes located by the
CpG markers significantly altered in KD3 vs FC or KD3 vs KD1 comparisons. Among the significant pathways (p< 0.05), four are co-enriched
in the two comparisons
Pathway name p-value: KD3 vs FC p-value: KD3 vs KD1
Hematopoietic cell lineage 4.10E-10 7.50E-09
Cytokine-cytokine receptor interaction 2.59E-09 9.52E-12
Chemokine signaling pathway 0.00246012 2.68E-05
Jak-STAT signaling pathway 0.00287132 0.000381639
Fig. 4 Methylation alteration in comparisons. There are 11 CpG markers that are significantly altered (p < 0.05, t-test) and carry more than 10 %
alteration in at least two of the three comparisons. For each CpG marker, the average methylation percentage in FC samples was set to 100 %.
The relative average methylation percentages in KD1 and KD3 samples were plotted. For cg20507276, the first two ‘*’ markers denote significant
alterations in KD1 vs. FC and KD3 vs. FC comparisons. The final ‘#’ mark denotes un-significant alteration between KD3 vs. KD1 comparison
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sticks to hypo-methylation status. Meanwhile, the last
three markers recover from the hypo-methylated status,
keeping no significant alteration from FC samples.
Altered change of gene expression between samples
DNA methylation on the CpG markers at genes’ pro-
moters are thought to decrease the expressions of the
downstream genes. Therefore, the methylation alteration
of CpG markers implies altered reversal change of gene
expression between samples. To investigate whether
negative correlation exists between DNA methylation
and gene expression or not we did further analysis on
FCGR2A gene which was reported to be a susceptibility
locus for KD [29, 30] and carries the CpG marker,
cg24422489, at its promoter region (-224 to the tran-
scription start site). As shown in Figs. 4 and 5a, in KD
samples, cg24422489 demonstrates a hypo-methated
status which was subsequently eliminated with the
hyper-methylation by the administration of IVIG. On
the contrary, the expression level of FCGR2A demon-
strates reverse tendency between samples. Such result
was summarized based on 18 methylation assays and 60
qPCR experiments (26 on FC, 24 on KD1 and 10 on
KD3 samples). For a more un-biased estimate, we did
re-sampling assay. For FCGR2A’s methylation β value
and ΔCt value, we did 10,000 runs of Bootstrap re-
sampleing [31, 32] individually in FC, KD1 and KD3 sets
followed by calculating the Pearson’s correlation coeffi-
cient of the 30,000 data points. The result shows that
methylation pattern is positively correlated with ΔCt
values (R = 0.62). Therefore, hyper-methylation at gene
promoter represses gene expression.
It is a consensus that hypermethylation at gene promoter
decreases the expressions of the downstream gene. How-
ever, not every hypermethylation brings down-regulation of
genes. Such cases can also be observed in our data. Actu-
ally, gene expression undergoes several regulation mecha-
nisms, including acetylation of chromatin [33], methylation
at CpG marker, the binding of transcription factor on pro-
moter [34], miRNA regulation [35] and so on. Therefore,
gene expression abundance is an overall result of all regula-
tion mechanisms. So far, it is difficult to monitor all regula-
tion mechanisms simultaneously so that only methylation
at CpG marker is considered in this study.
Conclusions
We first found that DNA methylation alterations reflect-
ing disease onset or IVIG administration are contributed
mainly by autosomes; sex chromosomes only contribute
little. In addition, some markers carry methylation alter-
ation between samples. As a result, their downstream
genes are also altered and are negatively correlated with
methylation profile. Finally, IVIG administration brings
stronger impact on methylation alteration than KD on-
sets does. And, such alterations were conducted mainly
by hyper-methylating CpG markers. Moreover, the genes
whose promoter CpG markers are altered with IVIG ad-
ministration are enriched in the pathways associated
with inflammatory immune response.
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